Pharma analyst Vishal Manchanda of Systematix Group highlighted Sun Pharma and Cipla as preferred picks because of their lower dependence on US generics. Sun has about 10-15% of sales exposed to the US market, while Cipla’s exposure is around 30%. But Cipla, he noted, manufactures many of its generic products in the US itself, reducing tariff risk.
